Neoplasms

All Conditions

Rare Diseases

Glioblastoma

Astrocytoma

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Administer combinations of up to 3 FDA approved drugs from a panel of compounds selected based on high throughput screening

combinations of up to 3 FDA approved drugs from a panel of compounds

Charles S Cobbs, M.D.

Parvinder Hothi, Ph.D.

Nathan Hansen

Charles S Cobbs

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.

A panel of FDA approved drugs will be tested by high throughput screening, which is CLIA certified allowing for clinical decisions based on the results, to identify a combination of up to 3 drug candidates for treating individual patients. Lead candidates will be evaluated by pharmacists and a team of physicians, to confirm that prescribed drugs do not utilize pharmacological/ metabolic pathways that are known to increase the likelihood of toxicity, prior to initiating treatment. Investigational drug therapy, targeting CSCs, will be initiated alongside standard of care chemoradiation with TMZ.

Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma

A Phase 1 Study of Combination Drug Therapy Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS) With Standard of Care for Newly Diagnosed Glioblastoma

incidence of treatment-related AEs, laboratory abnormalities, and SAEs as assessed by CTCAE version 5.0

Response assessment per Response Assessment in Neuro-Oncology (RANO) criteria

Swedish Medical Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma	NCT05380349	Newly Diagnosed...	combinations of...	18 Years -	Swedish Medical Center
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma	NCT05380349	Newly Diagnosed...	combinations of...	18 Years -	Swedish Medical Center

Spots Global Cancer Trial Database for combinations of up to 3 fda approved drugs from a panel of compounds